MUC1 and cancer: Over the past decades, many aptamers that specifically target cancer cells have been successfully selected, including AS1411 (nucleolin-targeted) [113,114], MUC1 (MUC1-targeted) [115], and Sgc8 (protein tyrosine kinase-7-targeted) [38], among others [39,74].